Teva and Blackstone Life Sciences agreed on a $400 million capital commitment payable over four years to fund ongoing and future development of duvakitug. Under the terms, Blackstone is eligible for regulatory and commercial milestone payments plus low single-digit royalties on global sales once duvakitug receives approval.

Duvakitug is a human monoclonal antibody targeting TL1A, currently in phase 3 trials for ulcerative colitis and Crohn’s disease with prior phase 2b data showing durable efficacy. Teva retains co-development and co-commercialization rights alongside Sanofi pending regulatory approval.

This partnership exemplifies Teva’s Pivot to Growth strategy, leveraging capital-efficient collaborations to advance its innovative pipeline while preserving balance-sheet strength. The funding accelerates Teva’s entry into the growing IBD market and underpins long-term growth objectives.